Furthermore, the treatment of melanoma cells carrying the BRAF mutation V600E with nanomolar concentrations of (Bu2Sn)2TPPS and (Bu3Sn)4TPPS induces the increased expression of BRAF, notwithstanding the fact these treatments also induce the inhibition of cellular growth, the blockage of the cell cycle, the inhibition of cell colony formation and the inhibition of the expression of a BRAF target such as cyclin D1 [51]. This evidence concerns the gene CCND1 and melanoma.